var data={"title":"Extragenital lichen sclerosus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Extragenital lichen sclerosus</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/contributors\" class=\"contributor contributor_credentials\">Heidi Jacobe, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/contributors\" class=\"contributor contributor_credentials\">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/contributors\" class=\"contributor contributor_credentials\">Abena O Ofori, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 06, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1945208\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lichen sclerosus (also known as lichen sclerosus et atrophicus) is a chronic inflammatory disorder characterized by the presence of porcelain white, atrophic plaques on the skin. Most cases of lichen sclerosus involve the female genitalia; extragenital manifestations occur in a minority of patients.</p><p>The epidemiology, clinical manifestations, and treatment of extragenital lichen sclerosus will be reviewed here. Anogenital lichen sclerosus is discussed separately. (See <a href=\"topic.htm?path=vulvar-lichen-sclerosus\" class=\"medical medical_review\">&quot;Vulvar lichen sclerosus&quot;</a> and <a href=\"topic.htm?path=balanitis-in-adults\" class=\"medical medical_review\">&quot;Balanitis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1945215\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extragenital manifestations are estimated to occur in approximately 15 to 20 percent of patients with lichen sclerosus [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/1\" class=\"abstract_t\">1</a>]. Similar to genital lichen sclerosus, extragenital disease appears to be more common in women than in men. In a retrospective review, 17 out of 20 patients with histopathologic findings consistent with extragenital lichen sclerosus were female [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/2\" class=\"abstract_t\">2</a>]. The disorder is rare in children.</p><p class=\"headingAnchor\" id=\"H1945222\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenesis of lichen sclerosus is not well understood, and most information on this subject has been derived from studies in genital disease. Proposed etiologic factors for lichen sclerosus have included immune dysfunction, genetic predisposition, infectious agents, and trauma [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/3-12\" class=\"abstract_t\">3-12</a>]. (See <a href=\"topic.htm?path=vulvar-lichen-sclerosus#H3\" class=\"medical medical_review\">&quot;Vulvar lichen sclerosus&quot;, section on 'Etiology'</a>.)</p><p class=\"headingAnchor\" id=\"H1945229\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extragenital lichen sclerosus can occur in any location on the skin and infrequently appears in the oral cavity. Concomitant vulvar or penile lichen sclerosus may or may not be present. Conjunctival lesions do not occur.</p><p class=\"headingAnchor\" id=\"H704587\"><span class=\"h2\">Cutaneous lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extragenital lesions are most commonly found on the back, shoulder, neck, wrist, thigh, and inframammary areas [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/1,13\" class=\"abstract_t\">1,13</a>]. Disease following the lines of Blaschko (<a href=\"image.htm?imageKey=PEDS%2F57219\" class=\"graphic graphic_figure graphicRef57219 \">figure 1</a>) also has been reported [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/14,15\" class=\"abstract_t\">14,15</a>]. </p><p>Early, active skin lesions of lichen sclerosus often appear as flat-topped and slightly scaly, hypopigmented, white, or mildly erythematous polygonal papules that may coalesce to form larger plaques with peripheral erythema (<a href=\"image.htm?imageKey=DERM%2F58815%7EDERM%2F70580%7EDERM%2F70084\" class=\"graphic graphic_picture graphicRef58815 graphicRef70580 graphicRef70084 \">picture 1A-C</a>). Over time, as activity subsides, lesions develop a porcelain white color, variable degrees of palpable sclerosis, and a cigarette paper-like wrinkled appearance that correlates with epidermal atrophy (<a href=\"image.htm?imageKey=DERM%2F74154%7EDERM%2F79867%7EDERM%2F60332\" class=\"graphic graphic_picture graphicRef74154 graphicRef79867 graphicRef60332 \">picture 2A-C</a>). In individuals with dark skin, established lesions may demonstrate hyperpigmentation and hypopigmentation rather than a porcelain white color (<a href=\"image.htm?imageKey=DERM%2F51592%7EDERM%2F59300\" class=\"graphic graphic_picture graphicRef51592 graphicRef59300 \">picture 3A-B</a>) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/16\" class=\"abstract_t\">16</a>]. Telangiectasias, follicular keratotic plugs, and hemorrhagic or nonhemorrhagic bullae may also be present (<a href=\"image.htm?imageKey=DERM%2F79659\" class=\"graphic graphic_picture graphicRef79659 \">picture 4</a>) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/17,18\" class=\"abstract_t\">17,18</a>].</p><p>Extragenital lichen sclerosus is often asymptomatic but may be severely disabling. Patients can experience pruritus or painful fissuring, particularly when lesions are located in areas subject to friction or tension, such as the inframammary folds, antecubital fossae, axillae, waist, inguinal creases, and popliteal fossae. Bullae may develop, often with hemorrhages resulting in erosions. In addition, trauma to unaffected skin, such as injury from tight clothing, injections, radiation therapy, herpes zoster, or other factors precipitate new lesions in some patients (Koebner phenomenon) (<a href=\"image.htm?imageKey=DERM%2F72972\" class=\"graphic graphic_picture graphicRef72972 \">picture 5</a>) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/11,12,19,20\" class=\"abstract_t\">11,12,19,20</a>].</p><p class=\"headingAnchor\" id=\"H704594\"><span class=\"h2\">Oral lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral lichen sclerosus is a rare manifestation of this disorder that involves the lips, gingiva, palate, tongue or buccal mucosa in children and adults [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/21-24\" class=\"abstract_t\">21-24</a>]. Lesions often appear as irregular white or hypopigmented plaques. Most patients are asymptomatic, but occasional patients experience pruritus, burning, or tightness in affected areas [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/21,22,25\" class=\"abstract_t\">21,22,25</a>]. Oral lesions may present independently or in association with lichen sclerosus in other sites [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/26\" class=\"abstract_t\">26</a>]. &#160;</p><p class=\"headingAnchor\" id=\"H238985308\"><span class=\"h2\">Concomitant morphea</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical findings consistent with genital or extragenital lichen sclerosus may occur in patients with morphea (<a href=\"image.htm?imageKey=DERM%2F82529%7EDERM%2F53986\" class=\"graphic graphic_picture graphicRef82529 graphicRef53986 \">picture 6A-B</a>) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/27-30\" class=\"abstract_t\">27-30</a>]. It is unclear whether the appearance of lesions consistent with lichen sclerosus represents the simultaneous occurrence of two separate disorders or the development of clinical findings that simply resemble lichen sclerosus in lesions of morphea. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-morphea-localized-scleroderma-in-adults#H8784269\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults&quot;, section on 'Lichen sclerosus'</a>.)</p><p>The frequency of extragenital lichen sclerosus in patients with morphea was evaluated in a retrospective study of 381 adults and 91 children with morphea [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/28\" class=\"abstract_t\">28</a>]. Extragenital lichen sclerosus was detected in 19 patients (4 percent). Additional studies are necessary to confirm the frequency of extragenital lichen sclerosus in this population. </p><p class=\"headingAnchor\" id=\"H704608\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of extragenital lichen sclerosus can often be made based upon the clinical appearance of lesions. When the diagnosis is uncertain, such as when features suggestive of other disorders are also present, a punch biopsy is useful for confirming the diagnosis. (See <a href=\"#H704623\" class=\"local\">'Differential diagnosis'</a> below and <a href=\"topic.htm?path=skin-biopsy-techniques#H12\" class=\"medical medical_review\">&quot;Skin biopsy techniques&quot;, section on 'Punch biopsy'</a>.)</p><p>The characteristic pathologic features of lichen sclerosus include (<a href=\"image.htm?imageKey=DERM%2F58841\" class=\"graphic graphic_picture graphicRef58841 \">picture 7</a>) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/2\" class=\"abstract_t\">2</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidermal hyperkeratosis with follicular plugging</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Epidermal atrophy with flattening of rete ridges</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Vacuolization of the basal layer of the epidermis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Marked edema in the superficial dermis (early lesions) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Homogenized collagen in the upper dermis (established lesions)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphohistiocytic infiltrate underlying the zone of homogenized collagen</p><p/><p>The identification of these histopathologic findings in lesions suspicious for lichen sclerosus is almost always indicative of the diagnosis. Although similar histopathologic findings occur in the lichen sclerosus-like variant of chronic graft-versus-host disease, the clinical history facilitates the differentiation of these disorders. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-graft-versus-host-disease-gvhd#H3566637\" class=\"medical medical_review\">&quot;Cutaneous manifestations of graft-versus-host disease (GVHD)&quot;, section on 'Diagnosis'</a> and <a href=\"#H704623\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H704623\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A variety of disorders may present with clinical features that resemble extragenital lichen sclerosus. Examples include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Vitiligo &ndash;</strong> Vitiligo is characterized by the presence of well-demarcated depigmented patches on the skin (<a href=\"image.htm?imageKey=DERM%2F74712%7EDERM%2F63623\" class=\"graphic graphic_picture graphicRef74712 graphicRef63623 \">picture 8A-B</a>). In contrast to lichen sclerosus, skin texture is normal, without signs of atrophy or sclerosis. (See <a href=\"topic.htm?path=vitiligo-pathogenesis-clinical-features-and-diagnosis#H79502398\" class=\"medical medical_review\">&quot;Vitiligo: Pathogenesis, clinical features, and diagnosis&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lichen planus &ndash;</strong> Lichen sclerosus may present as polygonal papules on the wrists or ankles that closely resemble lichen planus (<a href=\"image.htm?imageKey=DERM%2F76383%7EDERM%2F63590\" class=\"graphic graphic_picture graphicRef76383 graphicRef63590 \">picture 9A-B</a>) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/31,32\" class=\"abstract_t\">31,32</a>]. Unlike lichen sclerosus, lichen planus often is pruritic. A skin biopsy can be used to distinguish between these disorders. (See <a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">&quot;Lichen planus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tinea versicolor &ndash;</strong> Tinea versicolor presents with hypopigmented macules and patches primarily located on the trunk and proximal upper extremities (<a href=\"image.htm?imageKey=PC%2F72396%7EPC%2F73839\" class=\"graphic graphic_picture graphicRef72396 graphicRef73839 \">picture 10A-B</a>). Fine scale is often evident and a potassium hydroxide preparation will reveal the presence of fungal elements. Signs of cutaneous atrophy and sclerosis are absent. (See <a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor\" class=\"medical medical_review\">&quot;Tinea versicolor (Pityriasis versicolor)&quot;</a> and <a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures#H4044416\" class=\"medical medical_review\">&quot;Office-based dermatologic diagnostic procedures&quot;, section on 'Potassium hydroxide preparation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Anetoderma &ndash;</strong> In anetoderma, loss of elastin in the dermis contributes to reduced skin elasticity and the appearance of circumscribed, 1 to 3 cm areas of depressed, flaccid, wrinkled, or bulging skin (<a href=\"image.htm?imageKey=DERM%2F67581\" class=\"graphic graphic_picture graphicRef67581 \">picture 11</a>). Anetoderma may occur as a primary disorder or as a result of a preceding inflammatory process or other skin abnormality. The neck, trunk, and upper extremities are most frequently affected. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cutaneous T-cell lymphoma &ndash;</strong> Like lichen sclerosus, lesions of patch stage mycosis fungoides may present with epidermal atrophy manifesting as fine cigarette paper-like wrinkling (<a href=\"image.htm?imageKey=DERM%2F60650%7EHEME%2F63888\" class=\"graphic graphic_picture graphicRef60650 graphicRef63888 \">picture 12A-B</a>). Lesions of mycosis fungoides are often erythematous, resembling an eczematous dermatitis.<strong> </strong>(See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides#H8\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides&quot;, section on 'Skin lesions'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Chronic graft versus host disease &ndash;</strong> Patients who have received hematopoietic cell transplants may develop lesions that closely resemble extragenital lichen sclerosus as a manifestation of chronic graft-versus-host disease. Knowledge of the patient&rsquo;s transplant history is useful for diagnosis. (See <a href=\"topic.htm?path=cutaneous-manifestations-of-graft-versus-host-disease-gvhd#H877766\" class=\"medical medical_review\">&quot;Cutaneous manifestations of graft-versus-host disease (GVHD)&quot;, section on 'Sclerotic manifestations'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H1945250\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are few data on the efficacy of treatments for extragenital lichen sclerosus. Recommendations for the use of specific agents are primarily based upon case reports, small uncontrolled studies, and data from studies in genital disease. Patients with both morphea and lichen sclerosus are managed similarly to patients with morphea. (See <a href=\"topic.htm?path=treatment-of-morphea-localized-scleroderma-in-adults\" class=\"medical medical_review\">&quot;Treatment of morphea (localized scleroderma) in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20076616\"><span class=\"h2\">Approach to treatment of skin lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Extragenital lichen sclerosus is a benign, often asymptomatic condition when it occurs in isolated plaques; however, in some patients, the lesions are progressive and can involve large body surface areas. Therefore, follow up for progression is important. </p><p>Deferring treatment is a reasonable option in cases of limited skin involvement. Common reasons for initiating treatment include symptomatic, cosmetically distressing, extensive, or progressively worsening disease. </p><p>Topical medications, phototherapy, and systemic agents have been used for the treatment of extragenital lichen sclerosus; however, data on the efficacy of these treatments are limited. Potent topical corticosteroids are typically used as initial therapy due to their consistent efficacy in genital lichen sclerosus, reports of clinical experience documenting improvement in patients with extragenital lesions, and the ease of administration and relative safety of these agents. Other topical medications that have been associated with improvement in individual patients include topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> and topical <a href=\"topic.htm?path=calcipotriol-calcipotriene-drug-information\" class=\"drug drug_general\">calcipotriol</a>.</p><p>In the setting of widespread disease, application of topical corticosteroids to all lesions often is impractical. Phototherapy may be used for these patients. Phototherapy is also an option for the treatment of patients with disease that is refractory to topical corticosteroids or progressive. </p><p>Systemic therapy is rarely utilized for extragenital lichen sclerosus due to the relative paucity of efficacy data and the potential for severe adverse effects. Treatment with systemic agents is primarily reserved for patients with severe disease that has failed to respond to other treatments.</p><p>Providing patients with realistic expectations for treatment outcomes is an additional important component of patient management. Although symptoms and the appearance and texture of lesions can improve with treatment, lesions usually do not completely resolve. In our experience, active inflammatory lesions respond best, while inactive lesions with hypopigmentation and atrophy are unlikely to improve. If lesions are inactive, supportive therapy with emollients and wound care is indicated. </p><p>Wound care is important in the presence of fissures and erosions. Bland emollients (eg, petrolatum) and nonstick dressings are useful.</p><p class=\"headingAnchor\" id=\"H704636\"><span class=\"h2\">First-line therapies</span></p><p class=\"headingAnchor\" id=\"H704651\"><span class=\"h3\">Topical corticosteroids</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the efficacy of topical corticosteroids in extragenital lichen sclerosus has not been formally studied, improvement in genital disease during topical corticosteroid therapy has been reported in a randomized treatment comparison trial as well as uncontrolled and retrospective studies [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/33-36\" class=\"abstract_t\">33-36</a>]. Multiple reports of clinical experience documenting successful treatment of extragenital lichen sclerosus with superpotent topical corticosteroids also support the use of these agents for this disease [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/13,17,31,37-41\" class=\"abstract_t\">13,17,31,37-41</a>].</p><p>We typically prescribe once daily application of a superpotent agent, such as <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> propionate (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/13\" class=\"abstract_t\">13</a>]. Clinical experience suggests topical corticosteroids are less consistently effective for extragenital lesions than for genital lesions [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/13\" class=\"abstract_t\">13</a>], and if there is no improvement after two months, or if adverse effects are noted, we discontinue treatment and consider alternative therapies. Topical corticosteroids may also be used as an adjunctive treatment in patients receiving phototherapy or systemic therapy.</p><p>Potential adverse effects of topical corticosteroid therapy include local cutaneous atrophy and systemic absorption resulting in suppression of the hypothalamic-pituitary axis. Hypothalamic-pituitary axis suppression is most likely to occur with the use of high potency agents or during treatment of large areas. (See <a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use#H16\" class=\"medical medical_review\">&quot;General principles of dermatologic therapy and topical corticosteroid use&quot;, section on 'Side effects'</a>.)</p><p class=\"headingAnchor\" id=\"H704783\"><span class=\"h3\">Phototherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Phototherapy offers the ability to treat large areas of skin, thereby facilitating the treatment of patients with widespread lesions. We also use phototherapy as an alternative treatment for patients with more limited disease who have failed treatment with topical corticosteroids and in patients who are developing new lesions to suppress disease progression. </p><p>The mechanism through which phototherapy improves lichen sclerosus is unknown, but may involve factors such as the stimulation of matrix metalloproteinases and the depletion of proinflammatory cytokines [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/42\" class=\"abstract_t\">42</a>]. Additional studies are necessary to determine whether exposure of uninvolved skin during phototherapy prevents the development of new lesions; however, the author believes this might be a benefit of phototherapy.</p><p>Several forms of phototherapy have been used for the management of lichen sclerosus. The largest study involved the treatment of 10 patients with 40 sessions of ultraviolet A1 (UVA1) light at a dose of 20 <span class=\"nowrap\">J/cm<sup>2</sup></span> four times per week [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/43\" class=\"abstract_t\">43</a>]. All patients exhibited lesion softening and improvement in pigmentation. In addition, a few case reports have documented marked improvements in disease severity following treatment with narrowband ultraviolet B (UVB) light [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/38,42\" class=\"abstract_t\">38,42</a>]. </p><p>Psoralen plus ultraviolet A light (PUVA) involves the administration of an oral or topical photosensitizer (psoralen) prior to light treatment. Oral PUVA was effective in a patient who failed to respond to <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> propionate and topical <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/44\" class=\"abstract_t\">44</a>]. Oral PUVA also was used successfully in combination with topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> in a separate patient [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/45\" class=\"abstract_t\">45</a>]. The need for strict photoprotection following the oral administration of psoralens makes PUVA treatment less favorable than other forms of phototherapy for some patients.</p><p>Adverse effects of phototherapy include burning or blistering of skin and potential increased risks for premature skin aging and cutaneous malignancy. The risk for malignancy appears to be highest with long-term PUVA treatment. (See <a href=\"topic.htm?path=psoralen-plus-ultraviolet-a-puva-photochemotherapy\" class=\"medical medical_review\">&quot;Psoralen plus ultraviolet A (PUVA) photochemotherapy&quot;</a>.) </p><p class=\"headingAnchor\" id=\"H704934\"><span class=\"h2\">Other therapies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> appears to be less likely to be effective in extragenital lichen sclerosus than in genital lichen sclerosus. In a prospective uncontrolled study in which 16 patients with lichen sclerosus applied tacrolimus 0.1% ointment twice daily to affected areas, a partial or complete response was observed in 9 of 10 patients with anogenital lesions, but only 1 of 6 patients with extragenital lesions [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/46\" class=\"abstract_t\">46</a>]. The solitary patient with extragenital lichen sclerosus who improved achieved only a partial response. Topical <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a>, which also has been used successfully for vulvar disease [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/33\" class=\"abstract_t\">33</a>], was not effective for extragenital lichen sclerosus in a case report [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/47\" class=\"abstract_t\">47</a>]. We typically do not use topical tacrolimus or pimecrolimus for treatment of extragenital lichen sclerosus. (See <a href=\"topic.htm?path=vulvar-lichen-sclerosus#H690941642\" class=\"medical medical_review\">&quot;Vulvar lichen sclerosus&quot;, section on 'Topical calcineurin inhibitors'</a>.)</p><p>Treatments reported to be effective in small numbers of patients include topical <a href=\"topic.htm?path=calcipotriol-calcipotriene-drug-information\" class=\"drug drug_general\">calcipotriol</a> [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/48\" class=\"abstract_t\">48</a>], pulsed dye laser [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/49,50\" class=\"abstract_t\">49,50</a>], photodynamic therapy [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/50\" class=\"abstract_t\">50</a>], and carbon dioxide laser vaporization [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/51\" class=\"abstract_t\">51</a>]. Additional studies are necessary to determine the efficacies of these treatments for extragenital disease.</p><p class=\"headingAnchor\" id=\"H705066\"><span class=\"h2\">Refractory severe disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic immunosuppressive therapy is rarely used for the management of lichen sclerosus. It is a treatment option for severe disease in patients who have failed to respond to topical corticosteroids and phototherapy or who are unable to receive phototherapy. We typically treat these patients with a combination of systemic glucocorticoids and <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>.</p><p>The efficacy of glucocorticoids plus <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> is supported by a retrospective study of seven patients with progressively worsening extragenital lichen sclerosus that failed to respond to a potent topical corticosteroid (all patients) and phototherapy (six patients) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/52\" class=\"abstract_t\">52</a>]. Patients were treated with 15 mg per week of oral methotrexate and 1000 mg of intravenous <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> sodium succinate on three consecutive days per month. Treatment was continued for six months in six patients and for 10 months in one patient who had a delayed response to treatment. A significant decrease in a non-validated clinical disease severity score was detected at the end of treatment. In most patients, signs of improvement were first noted after three months of therapy.</p><p>Our typical treatment regimen includes 10 to 20 mg of oral <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> administered once <strong>per week</strong> plus oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> (1 <span class=\"nowrap\">mg/kg</span> per day or 40 to 60 mg per day). All patients given methotrexate also should receive <a href=\"topic.htm?path=folic-acid-drug-information\" class=\"drug drug_general\">folic acid</a> supplementation. Because absorption of oral methotrexate may be reduced at higher doses [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/53\" class=\"abstract_t\">53</a>], we often give methotrexate subcutaneously rather than orally when doses exceed 15 mg per week or when patients fail to respond adequately to oral therapy. Alternatively, we split the total dose of oral methotrexate into a morning and an evening dose or instruct the patient to take the second half of the dose on the following day. (See <a href=\"topic.htm?path=use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis#H2\" class=\"medical medical_review\">&quot;Use of methotrexate in the treatment of rheumatoid arthritis&quot;, section on 'Pharmacology'</a> and <a href=\"topic.htm?path=use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis#H12\" class=\"medical medical_review\">&quot;Use of methotrexate in the treatment of rheumatoid arthritis&quot;, section on 'Parenteral therapy'</a> and <a href=\"topic.htm?path=use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis\" class=\"medical medical_review\">&quot;Use of methotrexate in the treatment of rheumatoid arthritis&quot;</a>.)</p><p>We aim to taper the systemic glucocorticoid within the first three to six months of therapy, and begin the taper once disease progression has ceased, erythema has resolved, and lesion improvement is noted. The optimum duration of therapy with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> is not established. We generally maintain patients on the lowest effective dose, tapering over time as tolerated. </p><p>Monotherapy with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> has also been used successfully in a patient with extragenital disease [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/54\" class=\"abstract_t\">54</a>]. We generally reserve initial treatment with methotrexate alone for patients who have slow disease progression or who are poor candidates for systemic glucocorticoid therapy.</p><p>A variety of potential adverse effects are associated with treatment with <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> and glucocorticoids. Gastrointestinal distress is a common dose-related side effect of oral methotrexate therapy that may occur less frequently when methotrexate is given as parenteral therapy. We typically attempt subcutaneous therapy in patients who develop gastrointestinal side effects during oral therapy. (See <a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate\" class=\"medical medical_review\">&quot;Major side effects of low-dose methotrexate&quot;</a> and <a href=\"topic.htm?path=use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis#H12\" class=\"medical medical_review\">&quot;Use of methotrexate in the treatment of rheumatoid arthritis&quot;, section on 'Parenteral therapy'</a>.) </p><p>Use of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> is contraindicated in pregnancy, and relative contraindications for methotrexate therapy include alcohol abuse and preexisting liver disease. Dose adjustments of methotrexate are necessary in patients with renal insufficiency. The adverse effects of systemic glucocorticoids are reviewed separately. (See <a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate\" class=\"medical medical_review\">&quot;Major side effects of low-dose methotrexate&quot;</a> and <a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">&quot;Major side effects of systemic glucocorticoids&quot;</a>.)</p><p>The efficacy of other systemic therapies that have been used in genital lichen sclerosus (eg, oral retinoids, <a href=\"topic.htm?path=cyclosporine-ciclosporin-drug-information\" class=\"drug drug_general\">cyclosporine</a>) for extragenital disease is unknown. Improvement in extragenital lichen sclerosus complicated by bullae and ulceration during <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a> therapy was reported in one patient [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/55\" class=\"abstract_t\">55</a>].</p><p class=\"headingAnchor\" id=\"H20076853\"><span class=\"h2\">Treatment of oral lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of oral lesions of lichen sclerosus often is not required, and is usually only initiated in the setting of cosmetic concerns or symptoms. Treatments that have been associated with improvement in this disorder include superpotent or medium potency topical corticosteroids [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/23,56\" class=\"abstract_t\">23,56</a>], intralesional corticosteroid injections (10 <span class=\"nowrap\">mg/cc</span> <a href=\"topic.htm?path=triamcinolone-drug-information\" class=\"drug drug_general\">triamcinolone</a> acetonide) [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/57\" class=\"abstract_t\">57</a>], topical <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a> [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/26\" class=\"abstract_t\">26</a>], topical <a href=\"topic.htm?path=pimecrolimus-drug-information\" class=\"drug drug_general\">pimecrolimus</a> [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/25\" class=\"abstract_t\">25</a>], topical corticosteroids followed by topical <a href=\"topic.htm?path=testosterone-drug-information\" class=\"drug drug_general\">testosterone</a> [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/58\" class=\"abstract_t\">58</a>], surgical excision [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/22\" class=\"abstract_t\">22</a>], oral <a href=\"topic.htm?path=colchicine-drug-information\" class=\"drug drug_general\">colchicine</a> [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/22\" class=\"abstract_t\">22</a>], and oral <a href=\"topic.htm?path=griseofulvin-drug-information\" class=\"drug drug_general\">griseofulvin</a> [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/59\" class=\"abstract_t\">59</a>]. </p><p class=\"headingAnchor\" id=\"H1014337\"><span class=\"h2\">Morphea with lichen sclerosus features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with morphea who present with coexisting lesions consistent with lichen sclerosus should be managed similar to other morphea patients. (See <a href=\"#H704623\" class=\"local\">'Differential diagnosis'</a> above and <a href=\"topic.htm?path=treatment-of-morphea-localized-scleroderma-in-adults\" class=\"medical medical_review\">&quot;Treatment of morphea (localized scleroderma) in adults&quot;</a> and <a href=\"topic.htm?path=localized-scleroderma-in-childhood#H17\" class=\"medical medical_review\">&quot;Localized scleroderma in childhood&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H705439\"><span class=\"h1\">PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The natural history of extragenital lichen sclerosus has been poorly characterized. In our experience, the disease process often continues over the course of years, with unpredictable periods of exacerbation and stability. Although there is a strong link between genital lichen sclerosus and the development of genital squamous cell carcinoma, reports of the development of squamous cell carcinoma in sites of extragenital lichen sclerosus are rare [<a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/60,61\" class=\"abstract_t\">60,61</a>]. (See <a href=\"topic.htm?path=vulvar-lichen-sclerosus#H11\" class=\"medical medical_review\">&quot;Vulvar lichen sclerosus&quot;, section on 'Associated malignancy'</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=lichen-sclerosus-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Lichen sclerosus (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H1014499\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extragenital lichen sclerosus is an uncommon disorder that may involve the skin or oral cavity. The disorder occurs more frequently in women than in men, and the occurrence in children is rare. (See <a href=\"#H1945215\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Early active skin lesions of lichen sclerosus often present as flat-topped polygonal papules that may coalesce into large plaques (<a href=\"image.htm?imageKey=DERM%2F58815%7EDERM%2F70580%7EDERM%2F70084\" class=\"graphic graphic_picture graphicRef58815 graphicRef70580 graphicRef70084 \">picture 1A-C</a>). Inactive lesions frequently develop a porcelain-white color, a finely wrinkled surface, and variable degrees of sclerosis (<a href=\"image.htm?imageKey=DERM%2F74154%7EDERM%2F79867%7EDERM%2F60332\" class=\"graphic graphic_picture graphicRef74154 graphicRef79867 graphicRef60332 \">picture 2A-C</a>). In individuals with dark skin, lesions may be hyperpigmented or hypopigmented (<a href=\"image.htm?imageKey=DERM%2F51592%7EDERM%2F59300\" class=\"graphic graphic_picture graphicRef51592 graphicRef59300 \">picture 3A-B</a>). Oral lichen sclerosus presents as irregular white or hypopigmented plaques on the lips or in the oral cavity. (See <a href=\"#H1945229\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A variety of other skin disorders share clinical features with lichen sclerosus. When the diagnosis is uncertain based upon clinical examination, a skin biopsy should be performed. (See <a href=\"#H704608\" class=\"local\">'Diagnosis'</a> above and <a href=\"#H704623\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extragenital lichen sclerosus is a benign condition, and treatment may be deferred by patients who do not desire intervention. Common indications for proceeding with therapy include symptomatic, cosmetically distressing, extensive, or progressively worsening disease. (See <a href=\"#H20076616\" class=\"local\">'Approach to treatment of skin lesions'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with limited extragenital lichen sclerosus who desire treatment, we suggest treatment with a superpotent topical corticosteroid such as <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> propionate (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H704651\" class=\"local\">'Topical corticosteroids'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with widespread or progressive lesions, in whom application of topical therapy is impractical, or for patients who fail treatment with a superpotent topical corticosteroid, we suggest treatment with ultraviolet A1 (UVA1) phototherapy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). If UVA1 phototherapy is not available, patients may be treated with narrowband ultraviolet B (UVB) or psoralen plus ultraviolet A (PUVA). (See <a href=\"#H704783\" class=\"local\">'Phototherapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with severe disease that fails to respond to topical corticosteroids and phototherapy, we suggest treatment with a combination of <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a> (10 to 20 mg given on a weekly basis) and systemic glucocorticoids (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Other systemic treatments that have been reported to be effective in single patients include methotrexate alone and <a href=\"topic.htm?path=hydroxychloroquine-drug-information\" class=\"drug drug_general\">hydroxychloroquine</a>. (See <a href=\"#H705066\" class=\"local\">'Refractory severe disease'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Wound care is important in the presence of fissures and erosions and should include bland emollients (eg, petrolatum) and nonstick dressings.</p><p/><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/1\" class=\"nounderline abstract_t\">Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 1999; 353:1777.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/2\" class=\"nounderline abstract_t\">Carlson JA, Lamb P, Malfetano J, et al. Clinicopathologic comparison of vulvar and extragenital lichen sclerosus: histologic variants, evolving lesions, and etiology of 141 cases. Mod Pathol 1998; 11:844.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/3\" class=\"nounderline abstract_t\">Sander CS, Ali I, Dean D, et al. Oxidative stress is implicated in the pathogenesis of lichen sclerosus. Br J Dermatol 2004; 151:627.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/4\" class=\"nounderline abstract_t\">Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J Am Acad Dermatol 1995; 33:617.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/5\" class=\"nounderline abstract_t\">Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol 2000; 142:636.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/6\" class=\"nounderline abstract_t\">Cooper SM, Ali I, Baldo M, Wojnarowska F. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol 2008; 144:1432.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/7\" class=\"nounderline abstract_t\">Chan I, Oyama N, Neill SM, et al. Characterization of IgG autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Clin Exp Dermatol 2004; 29:499.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/8\" class=\"nounderline abstract_t\">Oyama N, Chan I, Neill SM, et al. Autoantibodies to extracellular matrix protein 1 in lichen sclerosus. Lancet 2003; 362:118.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/9\" class=\"nounderline abstract_t\">Oyama N, Chan I, Neill SM, et al. Development of antigen-specific ELISA for circulating autoantibodies to extracellular matrix protein 1 in lichen sclerosus. J Clin Invest 2004; 113:1550.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/10\" class=\"nounderline abstract_t\">Kowalewski C, Koz&#322;owska A, Chan I, et al. Three-dimensional imaging reveals major changes in skin microvasculature in lipoid proteinosis and lichen sclerosus. J Dermatol Sci 2005; 38:215.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/11\" class=\"nounderline abstract_t\">Anderton RL, Abele DC. Lichen sclerosus et atrophicus in a vaccination site. Arch Dermatol 1976; 112:1787.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/12\" class=\"nounderline abstract_t\">Yates VM, King CM, Dave VK. Lichen sclerosus et atrophicus following radiation therapy. Arch Dermatol 1985; 121:1044.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/13\" class=\"nounderline abstract_t\">Neill SM, Lewis FM, Tatnall FM, et al. British Association of Dermatologists' guidelines for the management of lichen sclerosus 2010. Br J Dermatol 2010; 163:672.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/14\" class=\"nounderline abstract_t\">Libow LF, Coots NV. Lichen sclerosus following the lines of Blaschko. J Am Acad Dermatol 1998; 38:831.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/15\" class=\"nounderline abstract_t\">Choi SW, Yang JE, Park HJ, Kim CW. A case of extragenital lichen sclerosus following Blaschko's lines. J Am Acad Dermatol 2000; 43:903.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/16\" class=\"nounderline abstract_t\">Farris DR, Hardy D, Kagen MH, et al. Extragenital pigmented lichen sclerosus. J Eur Acad Dermatol Venereol 2000; 14:322.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/17\" class=\"nounderline abstract_t\">Ballester I, Ba&ntilde;uls J, P&eacute;rez-Crespo M, Lucas A. Extragenital bullous lichen sclerosus atrophicus. Dermatol Online J 2009; 15:6.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/18\" class=\"nounderline abstract_t\">Garrido-R&iacute;os AA, Alvarez-Garrido H, Sanz-Mu&ntilde;oz C, et al. Dermoscopy of extragenital lichen sclerosus. Arch Dermatol 2009; 145:1468.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/19\" class=\"nounderline abstract_t\">Forschner A, Metzler G, Rassner G, Fierlbeck G. Morphea with features of lichen sclerosus et atrophicus at the site of a herpes zoster scar: another case of an isotopic response. Int J Dermatol 2005; 44:524.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/20\" class=\"nounderline abstract_t\">Noakes RR, Spelman L. K&ouml;bnerization in a woman with generalized lichen sclerosus. Australas J Dermatol 2004; 45:144.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/21\" class=\"nounderline abstract_t\">Attili VR, Attili SK. Lichen sclerosus of lips: a clinical and histopathologic study of 27 cases. Int J Dermatol 2010; 49:520.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/22\" class=\"nounderline abstract_t\">Azevedo RS, Roma&ntilde;ach MJ, de Almeida OP, et al. Lichen sclerosus of the oral mucosa: clinicopathological features of six cases. Int J Oral Maxillofac Surg 2009; 38:855.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/23\" class=\"nounderline abstract_t\">Kelly SC, Helm KF, Zaenglein AL. Lichen sclerosus of the lip. Pediatr Dermatol 2006; 23:500.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/24\" class=\"nounderline abstract_t\">Jensen T, Worsaae N, Melgaard B. Oral lichen sclerosus et atrophicus: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94:702.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/25\" class=\"nounderline abstract_t\">Kim CY, Kim JG, Oh CW. Treatment of oral lichen sclerosus with 1% pimecrolimus cream. Ann Dermatol 2010; 22:326.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/26\" class=\"nounderline abstract_t\">Wakamatsu J, Yamamoto T, Uchida H, Tsuboi R. Lichen sclerosus et atrophicus of the lip: successful treatment with topical tacrolimus. J Eur Acad Dermatol Venereol 2008; 22:760.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/27\" class=\"nounderline abstract_t\">Lutz V, Franc&egrave;s C, Bessis D, et al. High frequency of genital lichen sclerosus in a prospective series of 76 patients with morphea: toward a better understanding of the spectrum of morphea. Arch Dermatol 2012; 148:24.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/28\" class=\"nounderline abstract_t\">Kreuter A, Wischnewski J, Terras S, et al. Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center. J Am Acad Dermatol 2012; 67:1157.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/29\" class=\"nounderline abstract_t\">Uitto J, Santa Cruz DJ, Bauer EA, Eisen AZ. Morphea and lichen sclerosus et atrophicus. Clinical and histopathologic studies in patients with combined features. J Am Acad Dermatol 1980; 3:271.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/30\" class=\"nounderline abstract_t\">Tremaine R, Adam JE, Orizaga M. Morphea coexisting with lichen sclerosus et atrophicus. Int J Dermatol 1990; 29:486.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/31\" class=\"nounderline abstract_t\">V&aacute;zquez MG, Navarra R, Martin-Urda MT, et al. Lichen Sclerosus et Atrophicus with Cutaneous Distribution Simulating Lichen Planus. Case Rep Dermatol 2010; 2:55.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/32\" class=\"nounderline abstract_t\">Corbal&aacute;n-V&eacute;lez R, P&eacute;rez-Ferriols A. Lichen sclerosus et atrophicus affecting the wrists and left ankle and clinically simulating lichen planus. Cutis 2001; 67:417.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/33\" class=\"nounderline abstract_t\">Goldstein AT, Creasey A, Pfau R, et al. A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus. J Am Acad Dermatol 2011; 64:e99.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/34\" class=\"nounderline abstract_t\">Ayhan A, Guven S, Guvendag Guven ES, et al. Topical testosterone versus clobetasol for vulvar lichen sclerosus. Int J Gynaecol Obstet 2007; 96:117.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/35\" class=\"nounderline abstract_t\">Lorenz B, Kaufman RH, Kutzner SK. Lichen sclerosus. Therapy with clobetasol propionate. J Reprod Med 1998; 43:790.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/36\" class=\"nounderline abstract_t\">Dalziel KL, Millard PR, Wojnarowska F. The treatment of vulval lichen sclerosus with a very potent topical steroid (clobetasol propionate 0.05%) cream. Br J Dermatol 1991; 124:461.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/37\" class=\"nounderline abstract_t\">Sauder MB, Linzon-Smith J, Beecker J. Extragenital bullous lichen sclerosus. J Am Acad Dermatol 2014; 71:981.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/38\" class=\"nounderline abstract_t\">Colbert RL, Chiang MP, Carlin CS, Fleming M. Progressive extragenital lichen sclerosus successfully treated with narrowband UV-B phototherapy. Arch Dermatol 2007; 143:19.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/39\" class=\"nounderline abstract_t\">Chen JF, Chiang CP, Chen YF. Bilateral zosteriform extragenital lichen sclerosus et atrophicus: a new clinical presentation. J Dermatol 2010; 37:480.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/40\" class=\"nounderline abstract_t\">Bergstrom KG, Mengden SJ, Kamino H, Ramsay D. Extragenital lichen sclerosus et atrophicus. Dermatol Online J 2008; 14:23.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/41\" class=\"nounderline abstract_t\">Marren P, De Berker D, Millard P, Wojnarowska F. Bullous and haemorrhagic lichen sclerosus with scalp involvement. Clin Exp Dermatol 1992; 17:354.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/42\" class=\"nounderline abstract_t\">Kreuter A, Gambichler T. Narrowband UV-B phototherapy for extragenital lichen sclerosus. Arch Dermatol 2007; 143:1213.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/43\" class=\"nounderline abstract_t\">Kreuter A, Gambichler T, Avermaete A, et al. Low-dose ultraviolet A1 phototherapy for extragenital lichen sclerosus: results of a preliminary study. J Am Acad Dermatol 2002; 46:251.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/44\" class=\"nounderline abstract_t\">Dalmau J, Baselga E, Ro&eacute; E, Alomar A. Psoralen-UVA treatment for generalized prepubertal extragenital lichen sclerosus et atrophicus. J Am Acad Dermatol 2006; 55:S56.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/45\" class=\"nounderline abstract_t\">Valdivielso-Ramos M, Bueno C, Hernanz JM. Significant improvement in extensive lichen sclerosus with tacrolimus ointment and PUVA. Am J Clin Dermatol 2008; 9:175.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/46\" class=\"nounderline abstract_t\">Kim GW, Park HJ, Kim HS, et al. Topical tacrolimus ointment for the treatment of lichen sclerosus, comparing genital and extragenital involvement. J Dermatol 2012; 39:145.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/47\" class=\"nounderline abstract_t\">Arican O, Ciralik H, Sasmaz S. Unsuccessful treatment of extragenital lichen sclerosus with topical 1% pimecrolimus cream. J Dermatol 2004; 31:1014.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/48\" class=\"nounderline abstract_t\">Kreuter A, Gambichler T, Sauermann K, et al. Extragenital lichen sclerosus successfully treated with topical calcipotriol: evaluation by in vivo confocal laser scanning microscopy. Br J Dermatol 2002; 146:332.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/49\" class=\"nounderline abstract_t\">Greve B, Hartschuh W, Raulin C. [Extragenital lichen sclerosus et atrophicus - treatment with pulsed dye laser]. Hautarzt 1999; 50:805.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/50\" class=\"nounderline abstract_t\">Passeron T, Lacour JP, Ortonne JP. Comparative treatment of extragenital lichen sclerosus with methylaminolevulinic Acid pulsed dye laser-mediated photodynamic therapy or pulsed dye laser alone. Dermatol Surg 2009; 35:878.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/51\" class=\"nounderline abstract_t\">Kartamaa M, Reitamo S. Treatment of lichen sclerosus with carbon dioxide laser vaporization. Br J Dermatol 1997; 136:356.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/52\" class=\"nounderline abstract_t\">Kreuter A, Tigges C, Gaifullina R, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate treatment in patients with refractory generalized extragenital lichen sclerosus. Arch Dermatol 2009; 145:1303.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/53\" class=\"nounderline abstract_t\">Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004; 31:645.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/54\" class=\"nounderline abstract_t\">Nayeemuddin F, Yates VM. Lichen sclerosus et atrophicus responding to methotrexate. Clin Exp Dermatol 2008; 33:651.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/55\" class=\"nounderline abstract_t\">Wakelin SH, James MP. Extensive lichen sclerosus et atrophicus with bullae and ulceration--improvement with hydroxychloroquine. Clin Exp Dermatol 1994; 19:332.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/56\" class=\"nounderline abstract_t\">Rajlawat BP, Triantafyllou A, Field EA, Parslew R. Lichen sclerosus of the lip and buccal mucosa. Clin Exp Dermatol 2004; 29:684.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/57\" class=\"nounderline abstract_t\">Buajeeb W, Kraivaphan P, Punyasingh J, Laohapand P. Oral lichen sclerosus et atrophicus. A case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 88:702.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/58\" class=\"nounderline abstract_t\">Brown AR, Dunlap CL, Bussard DA, Lask JT. Lichen sclerosus et atrophicus of the oral cavity: report of two cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84:165.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/59\" class=\"nounderline abstract_t\">Macleod RI, Soames JV. Lichen sclerosus et atrophicus of the oral mucosa. Br J Oral Maxillofac Surg 1991; 29:64.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/60\" class=\"nounderline abstract_t\">Sergeant A, Vernall N, Mackintosh LJ, et al. Squamous cell carcinoma arising in extragenital lichen sclerosus. Clin Exp Dermatol 2009; 34:e278.</a></li><li><a href=\"https://www.uptodate.com/contents/extragenital-lichen-sclerosus/abstract/61\" class=\"nounderline abstract_t\">Sotillo Gago I, Mart&iacute;nez Sahuquillo A, Matilla A, Garc&iacute;a P&eacute;rez A. [Spinocellular epithelioma following scleroatrophic autoaneous licher]. Actas Dermosifiliogr 1977; 68:219.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15838 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1014499\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1945208\" id=\"outline-link-H1945208\">INTRODUCTION</a></li><li><a href=\"#H1945215\" id=\"outline-link-H1945215\">EPIDEMIOLOGY</a></li><li><a href=\"#H1945222\" id=\"outline-link-H1945222\">PATHOGENESIS</a></li><li><a href=\"#H1945229\" id=\"outline-link-H1945229\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H704587\" id=\"outline-link-H704587\">Cutaneous lesions</a></li><li><a href=\"#H704594\" id=\"outline-link-H704594\">Oral lesions</a></li><li><a href=\"#H238985308\" id=\"outline-link-H238985308\">Concomitant morphea</a></li></ul></li><li><a href=\"#H704608\" id=\"outline-link-H704608\">DIAGNOSIS</a></li><li><a href=\"#H704623\" id=\"outline-link-H704623\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H1945250\" id=\"outline-link-H1945250\">TREATMENT</a><ul><li><a href=\"#H20076616\" id=\"outline-link-H20076616\">Approach to treatment of skin lesions</a></li><li><a href=\"#H704636\" id=\"outline-link-H704636\">First-line therapies</a><ul><li><a href=\"#H704651\" id=\"outline-link-H704651\">- Topical corticosteroids</a></li><li><a href=\"#H704783\" id=\"outline-link-H704783\">- Phototherapy</a></li></ul></li><li><a href=\"#H704934\" id=\"outline-link-H704934\">Other therapies</a></li><li><a href=\"#H705066\" id=\"outline-link-H705066\">Refractory severe disease</a></li><li><a href=\"#H20076853\" id=\"outline-link-H20076853\">Treatment of oral lesions</a></li><li><a href=\"#H1014337\" id=\"outline-link-H1014337\">Morphea with lichen sclerosus features</a></li></ul></li><li><a href=\"#H705439\" id=\"outline-link-H705439\">PROGNOSIS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H12992032\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H1014499\" id=\"outline-link-H1014499\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15838|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/57219\" class=\"graphic graphic_figure\">- Lines of Blaschko</a></li></ul></li><li><div id=\"DERM/15838|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/58815\" class=\"graphic graphic_picture\">- Lichen sclerosus papules and plaques on wrist</a></li><li><a href=\"image.htm?imageKey=DERM/70580\" class=\"graphic graphic_picture\">- Lichen sclerosus on the wrist</a></li><li><a href=\"image.htm?imageKey=DERM/70084\" class=\"graphic graphic_picture\">- Lichen sclerosus papules on the chest</a></li><li><a href=\"image.htm?imageKey=DERM/74154\" class=\"graphic graphic_picture\">- Lichen sclerosus - trunk</a></li><li><a href=\"image.htm?imageKey=DERM/79867\" class=\"graphic graphic_picture\">- Lichen sclerosus on the breast</a></li><li><a href=\"image.htm?imageKey=DERM/60332\" class=\"graphic graphic_picture\">- Lichen sclerosus on the chest</a></li><li><a href=\"image.htm?imageKey=DERM/51592\" class=\"graphic graphic_picture\">- Extragenital lichen sclerosus in dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/59300\" class=\"graphic graphic_picture\">- Lichen sclerosus on the wrists in dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/79659\" class=\"graphic graphic_picture\">- Lichen sclerosus follicular plugging</a></li><li><a href=\"image.htm?imageKey=DERM/72972\" class=\"graphic graphic_picture\">- Lichen sclerosus in sites of friction</a></li><li><a href=\"image.htm?imageKey=DERM/82529\" class=\"graphic graphic_picture\">- Morphea and lichen sclerosus</a></li><li><a href=\"image.htm?imageKey=DERM/53986\" class=\"graphic graphic_picture\">- Morphea with features of lichen sclerosus</a></li><li><a href=\"image.htm?imageKey=DERM/58841\" class=\"graphic graphic_picture\">- Lichen sclerosus - histopathology</a></li><li><a href=\"image.htm?imageKey=DERM/74712\" class=\"graphic graphic_picture\">- Vitiligo - elbow</a></li><li><a href=\"image.htm?imageKey=DERM/63623\" class=\"graphic graphic_picture\">- Vitiligo - hands</a></li><li><a href=\"image.htm?imageKey=DERM/76383\" class=\"graphic graphic_picture\">- Lichen planus wrists fair skin</a></li><li><a href=\"image.htm?imageKey=DERM/63590\" class=\"graphic graphic_picture\">- Lichen planus flexures dark skin</a></li><li><a href=\"image.htm?imageKey=PC/72396\" class=\"graphic graphic_picture\">- Tinea versicolor back</a></li><li><a href=\"image.htm?imageKey=PC/73839\" class=\"graphic graphic_picture\">- Tinea versicolor shoulder</a></li><li><a href=\"image.htm?imageKey=DERM/67581\" class=\"graphic graphic_picture\">- Anetoderma</a></li><li><a href=\"image.htm?imageKey=DERM/60650\" class=\"graphic graphic_picture\">- Mycosis fungoides patches</a></li><li><a href=\"image.htm?imageKey=HEME/63888\" class=\"graphic graphic_picture\">- Mycosis fungoides poikiloderma</a></li></ul></li><li><div id=\"DERM/15838|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=balanitis-in-adults\" class=\"medical medical_review\">Balanitis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-mycosis-fungoides\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-manifestations-of-graft-versus-host-disease-gvhd\" class=\"medical medical_review\">Cutaneous manifestations of graft-versus-host disease (GVHD)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=general-principles-of-dermatologic-therapy-and-topical-corticosteroid-use\" class=\"medical medical_review\">General principles of dermatologic therapy and topical corticosteroid use</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">Lichen planus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=localized-scleroderma-in-childhood\" class=\"medical medical_review\">Localized scleroderma in childhood</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-low-dose-methotrexate\" class=\"medical medical_review\">Major side effects of low-dose methotrexate</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=major-side-effects-of-systemic-glucocorticoids\" class=\"medical medical_review\">Major side effects of systemic glucocorticoids</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=office-based-dermatologic-diagnostic-procedures\" class=\"medical medical_review\">Office-based dermatologic diagnostic procedures</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-morphea-localized-scleroderma-in-adults\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lichen-sclerosus-the-basics\" class=\"medical medical_basics\">Patient education: Lichen sclerosus (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=psoralen-plus-ultraviolet-a-puva-photochemotherapy\" class=\"medical medical_review\">Psoralen plus ultraviolet A (PUVA) photochemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=skin-biopsy-techniques\" class=\"medical medical_review\">Skin biopsy techniques</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tinea-versicolor-pityriasis-versicolor\" class=\"medical medical_review\">Tinea versicolor (Pityriasis versicolor)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-morphea-localized-scleroderma-in-adults\" class=\"medical medical_review\">Treatment of morphea (localized scleroderma) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-methotrexate-in-the-treatment-of-rheumatoid-arthritis\" class=\"medical medical_review\">Use of methotrexate in the treatment of rheumatoid arthritis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vitiligo-pathogenesis-clinical-features-and-diagnosis\" class=\"medical medical_review\">Vitiligo: Pathogenesis, clinical features, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=vulvar-lichen-sclerosus\" class=\"medical medical_review\">Vulvar lichen sclerosus</a></li></ul></div></div>","javascript":null}